爱德华生命科学

最新新闻

• 评级变动
  Jefferies Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $105
  Market Newswire · 2026/9/11
• 评级变动
  BTIG Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $110
  Market Newswire · 2026/9/11
• 公司公告
  TELA Bio | 4: Statement of changes in beneficial ownership of securities-10% Owner EW HEALTHCARE PARTNERS FUND 2, L.P.
  SEC · 2024/2/17
• 评级变动
  TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $104
  Market Newswire · 2026/7/22
• UBS Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $110
  Market Newswire · 2026/10/8
• 公司公告
  TELA Bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-EW Healthcare Partners Fund 2-UGP, LLC(10.44%),EW Healthcare Partners Fund 2-GP, L.P.(10.44%), etc.
  SEC · 2024/10/29
• 评级变动
  William Blair Maintains Edwards Lifesciences(EW.US) With Buy Rating
  Market Newswire · 2026/9/11
• 评级变动
  A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $95 to $110
  Market Newswire · 2026/7/25
• 评级变动
  J.P. Morgan Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $105
  Market Newswire · 2026/7/29
• RBC Capital Initiates Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $110
  Market Newswire · 2026/10/3
• 评级变动
  BofA Securities Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $100
  Market Newswire · 2026/7/22
• 公司公告
  TELA Bio | 3/A: Initial statement of beneficial ownership of securities (Amendment)-10% Owner EW HEALTHCARE PARTNERS FUND 2, L.P.
  SEC · 2024/2/17
• Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $110
  Market Newswire · 2026/10/5
• Jefferies Initiates Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $110
  Market Newswire · 2026/10/8
• Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $110
  Market Newswire · 2026/10/7
• 公司公告
  TELA Bio | SC 13G: Statement of acquisition of beneficial ownership by individuals-EW Healthcare Partners Fund 2-UGP, LLC(16.79%),EW Healthcare Partners Fund 2 GP, L.P.(16.79%), etc.
  SEC · 2024/2/14
• 公司公告
  TELA Bio | 4: Statement of changes in beneficial ownership of securities-10% Owner EW HEALTHCARE PARTNERS FUND 2, L.P.
  SEC · 2025/11/18
• 评级变动
  UBS Upgrades Edwards Lifesciences(EW.US) to Buy Rating, Raises Target Price to $110
  Market Newswire · 2026/7/28
• 评级变动
  Leerink Partners Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $101
  Market Newswire · 2026/9/29
• 评级变动
  Piper Sandler Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $101
  Market Newswire · 2026/9/21
• 评级变动
  Citi Maintains Edwards Lifesciences(EW.US) With Buy Rating, Maintains Target Price $110
  Market Newswire · 2026/9/10
• 评级变动
  Evercore Maintains Edwards Lifesciences(EW.US) With Buy Rating, Announces Target Price $100
  Market Newswire · 2026/7/6
• 评级变动
  Truist Financial Maintains Edwards Lifesciences(EW.US) With Hold Rating, Announces Target Price $95
  Market Newswire · 2026/7/16
• 评级变动
  Mizuho Securities Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $105
  Market Newswire · 2026/7/15
• 评级变动
  RBC Capital Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $110
  Market Newswire · 2026/7/13

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。